Download PDF
1 / Pages

Other users also viewed these articles

Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents Diego García-Compeán; Ramesh Kumar; Ángel Noe del Cueto-Aguilera; Héctor Jesús Maldonado-Garza; Jesús Zacarías Villarreal-Pérez;
Ann Hepatol. 2023;28:
The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease Francisco Barrera; Javier Uribe; Nixa Olvares; Paula Huerta; Daniel Cabrera; Manuel Romero-Gómez;
Ann Hepatol. 2024;29:
Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease Juan Pablo Arab; Melisa Dirchwolf; Mário Reis Álvares-da-Silva; Francisco Barrera; Carlos Benítez; Marlene Castellanos-Fernandez; Graciela Castro-Narro; Norberto Chavez-Tapia; Daniela Chiodi; Helma Cotrim; Kenneth Cusi; Claudia Pinto Marques Souza de Oliveira; Javier Díaz; Eduardo Fassio; Solange Gerona; Marcos Girala; Nelia Hernandez; Sebastián Marciano; Walter Masson; Nahum Méndez-Sánchez; Nathalie Leite; Adelina Lozano; Martín Padilla; Arturo Panduro; Raymundo Paraná; Edison Parise; Marlene Perez; Jaime Poniachik; Juan Carlos Restrepo; Andrés Ruf; Marcelo Silva; Martín Tagle; Monica Tapias; Kenia Torres; Eduardo Vilar-Gomez; José Eduardo Costa Gil; Adrian Gadano; Marco Arrese;
Ann Hepatol. 2020;19:674-90